Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

Original reporting
Published Oct 21, 2026, 7:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 7:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$IARTBearishMed
01

Why it matters

The earnings release introduces a downward revision to full‑year revenue guidance and confirms unprofitability, likely prompting short‑term selling pressure.

02

Market read

First‑time earnings disclosure with guidance cut; material for traders watching healthcare device stocks.

03

What to watch

Strong cash flow generation ($96M operating cash flow) and improving leverage (3.8x) may support a rebound once disruptions ease.

Relevance 7/10Novelty 8/10Timing: after‑hours release today

Background

Integra LifeSciences (IART) is a mid‑cap medical‑device company focused on neurosurgical and tissue‑technology products. The report follows a period of operational disruptions that trimmed revenue.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences reported Q3 revenue of $411M, meeting the low end of guidance and cut full-year revenue outlook by $30M due to operational disruptions.

Expected impact

likely downward pressure as the market prices in weaker revenue outlook and lower full‑year guidance

Evidence & confidence

The earnings release contains fresh guidance cuts and lower‑than‑expected revenue, which historically trigger sell‑offs in mid‑cap medical‑device stocks.

Market effects

May prompt re‑rating of other mid‑cap medical‑device companies as investors reassess demand and operational risk.

Limited to U.S. and European medical‑device markets; no broad regional effect.

Low global impact; relevance confined to the healthcare device sector.

Counterpoint

The low price‑to‑sales multiple (0.57) could signal a deep discount, offering a value entry if the operational disruptions are temporary.

Key entities

  • Integra LifeSciences Holdings Corp

    Medical‑device manufacturer reporting Q3 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.